CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Novartis Adr Repsg 1 - USD - NVS CFD

    97.22
    2.3%
    0.14
    Low: 97.05
    High: 98.4
    Market Trading Hours* (UTC) Opens on Wednesday at 13:30

    Mon - Fri: 13:30 - 20:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.14
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Novartis AG ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 95.03
    Open* 97.65
    1-Year Change* -2.64%
    Day's Range* 97.05 - 98.4
    52 wk Range 75.68-108.41
    Average Volume (10 days) 1.37M
    Average Volume (3 months) 31.52M
    Market Cap 245.41B
    P/E Ratio 30.64
    Shares Outstanding 2.06B
    Revenue 47.89B
    EPS 3.53
    Dividend (Yield %) 3.23864
    Beta 0.56
    Next Earnings Date Jan 31, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 22, 2024 95.03 0.38 0.40% 94.65 95.97 94.61
    Apr 19, 2024 94.27 1.15 1.23% 93.12 94.44 92.93
    Apr 18, 2024 92.50 -0.27 -0.29% 92.77 92.85 92.27
    Apr 17, 2024 93.02 -0.50 -0.53% 93.52 93.73 92.79
    Apr 16, 2024 93.11 0.38 0.41% 92.73 93.31 92.49
    Apr 15, 2024 94.30 0.19 0.20% 94.11 94.91 94.03
    Apr 12, 2024 93.48 -1.37 -1.44% 94.85 95.01 93.30
    Apr 11, 2024 94.29 -0.54 -0.57% 94.83 94.83 93.64
    Apr 10, 2024 94.30 -0.18 -0.19% 94.48 94.60 93.96
    Apr 9, 2024 95.72 0.11 0.12% 95.61 95.84 95.30
    Apr 8, 2024 95.42 -0.21 -0.22% 95.63 96.08 95.18
    Apr 5, 2024 95.71 0.47 0.49% 95.24 95.87 94.96
    Apr 4, 2024 96.83 -0.18 -0.19% 97.01 98.13 96.47
    Apr 3, 2024 94.30 -0.14 -0.15% 94.44 94.82 94.06
    Apr 2, 2024 94.35 -0.14 -0.15% 94.49 94.54 93.84
    Apr 1, 2024 95.78 -1.07 -1.10% 96.85 96.92 95.33
    Mar 28, 2024 96.48 0.31 0.32% 96.17 97.14 96.08
    Mar 27, 2024 95.83 0.36 0.38% 95.47 95.84 95.20
    Mar 26, 2024 95.20 -0.27 -0.28% 95.47 95.50 95.00
    Mar 25, 2024 95.70 -0.38 -0.40% 96.08 96.23 95.69

    Novartis Adr Repsg 1 - USD Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 51742 52877 49898 48624 46017
    Revenue 51742 52877 49898 48624 46017
    Cost of Revenue, Total 14998 15435 14400 13930 13555
    Gross Profit 36744 37442 35498 34694 32462
    Total Operating Expense 42545 41188 39746 39538 31824
    Selling/General/Admin. Expenses, Total 14190 14815 14093 14319 13690
    Research & Development 9088 9041 8484 8386 8154
    Depreciation / Amortization 158 109 64 50 179
    Unusual Expense (Income) 3402 1173 2503 2284 -4309
    Other Operating Expenses, Total 449 653 538 607 549
    Operating Income 9197 11689 10152 9086 14193
    Interest Income (Expense), Net Non-Operating -543 14628 -146 -36 -5
    Other, Net -283 -180 -128 -110 -93
    Net Income Before Taxes 8371 26137 9878 8940 14095
    Net Income After Taxes 6955 24018 8071 7147 12800
    Minority Interest 0 3 1 -5 -3
    Net Income Before Extra. Items 6955 24021 8072 7142 12797
    Net Income 6955 24021 8072 11732 12611
    Income Available to Common Excl. Extra. Items 6955 24021 8072 7142 12797
    Income Available to Common Incl. Extra. Items 6955 24021 8072 11732 12611
    Dilution Adjustment
    Diluted Net Income 6955 24021 8072 11732 12611
    Diluted Weighted Average Shares 2197 2260 2296 2319 2344
    Diluted EPS Excluding Extraordinary Items 3.16568 10.6288 3.51568 3.07978 5.45947
    Dividends per Share - Common Stock Primary Issue 3.46171 3.19907 3.08737 2.83413 2.93645
    Diluted Normalized EPS 4.47075 11.1183 4.40641 3.86715 3.79006
    Total Extraordinary Items 4590 -186
    Interest Expense (Income) - Net Operating 260 -38 -336 -38 6
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total revenue 12092 22792 13208 13001 10783
    Revenue 12092 22792 13208 13001 10783
    Cost of Revenue, Total 3089 5944 3829 3837 2874
    Gross Profit 9003 16848 9379 9164 7909
    Total Operating Expense 10330 17367 10352 11052 8957
    Selling/General/Admin. Expenses, Total 3093 5952 3401 3699 2936
    Research & Development 2187 4182 2272 2318 2542
    Depreciation / Amortization 169 198 153 42
    Interest Expense (Income) - Net Operating -6 69 46 -28 90
    Unusual Expense (Income) 1751 648 298 1145 302
    Other Operating Expenses, Total 47 374 353 39 213
    Operating Income 1762 5425 2856 1949 1826
    Interest Income (Expense), Net Non-Operating -225 -420 -212 -222 -211
    Other, Net 15 189 96 14 -28
    Net Income Before Taxes 1552 5194 2740 1741 1587
    Net Income After Taxes 1513 4421 2294 1466 1330
    Minority Interest -2 -2 -1 0 -2
    Net Income Before Extra. Items 1511 4419 2293 1466 1328
    Net Income 1761 4609 2293 1466 1573
    Income Available to Common Excl. Extra. Items 1511 4419 2293 1466 1328
    Income Available to Common Incl. Extra. Items 1761 4609 2293 1466 1573
    Diluted Net Income 1761 4609 2293 1466 1573
    Diluted Weighted Average Shares 2075 2086.5 2120 2158 2180
    Diluted EPS Excluding Extraordinary Items 0.72819 2.1179 1.0816 0.67933 0.60917
    Dividends per Share - Common Stock Primary Issue 0 0 0 3.46171 0
    Diluted Normalized EPS 1.55084 2.38225 1.20956 1.14055 0.72527
    Total Extraordinary Items 250 190 245
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 36910 45718 29673 29504 35563
    Cash and Short Term Investments 18726 28113 11293 11234 15718
    Cash 2877 3396 3750 3247 3121
    Cash & Equivalents 4640 9011 5908 7865 10150
    Short Term Investments 11209 15706 1635 122 2447
    Total Receivables, Net 9894 9621 10036 10337 11036
    Accounts Receivable - Trade, Net 8066 8005 8217 8301 8739
    Total Inventory 7175 6666 7131 5982 6956
    Prepaid Expenses 911 1102 943 898 812
    Other Current Assets, Total 204 216 270 1053 1041
    Total Assets 117453 131795 127778 118370 145563
    Property/Plant/Equipment, Total - Net 12195 13106 13939 13746 15696
    Property/Plant/Equipment, Total - Gross 26304 28708 29894 28676 34028
    Accumulated Depreciation, Total -14109 -15602 -15955 -14930 -18332
    Goodwill, Net 29301 29595 29999 26524 35294
    Intangibles, Net 31644 34182 36809 28787 38719
    Long Term Investments 1606 2268 11611 10538 9789
    Note Receivable - Long Term 948 973 922 624 908
    Other Long Term Assets, Total 4849 5953 4825 8647 9594
    Total Current Liabilities 28656 30208 33059 28264 29607
    Accounts Payable 5146 5553 5403 5424 5556
    Accrued Expenses 5334 5100 5336 5058 5105
    Notes Payable/Short Term Debt 3635 3606 7319 4844 6430
    Current Port. of LT Debt/Capital Leases 2492 2896 2558 2248 3190
    Other Current Liabilities, Total 12049 13053 12443 10690 9326
    Total Liabilities 58111 64140 71180 62896 66949
    Total Long Term Debt 21782 24523 27978 22056 22470
    Long Term Debt 20244 22902 26259 20353 22470
    Deferred Income Tax 2686 3070 3141 5867 7475
    Minority Interest 81 167 68 77 78
    Other Liabilities, Total 4906 6172 6934 6632 7319
    Total Equity 59342 67655 56598 55474 78614
    Common Stock 890 901 913 936 944
    Retained Earnings (Accumulated Deficit) 63540 70989 57157 59274 82191
    Treasury Stock - Common -92 -48 -53 -80 -69
    Unrealized Gain (Loss) -198 206
    Other Equity, Total -4798 -4187 -1419 -4656 -4658
    Total Liabilities & Shareholders’ Equity 117453 131795 127778 118370 145563
    Total Common Shares Outstanding 2119.61 2234.94 2256.82 2265.01 2311.17
    Capital Lease Obligations 1538 1621 1719 1703
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 45660 33493 32114 36910 36954
    Cash and Short Term Investments 12695 11174 12260 18930 19103
    Cash & Equivalents 12405 10885 12000 7517 8726
    Short Term Investments 290 289 260 11413 10377
    Total Receivables, Net 7099 9543 9183 8334 8680
    Accounts Receivable - Trade, Net 6819 9195 8916 8066 8422
    Total Inventory 5610 8228 7886 7175 6779
    Other Current Assets, Total 20256 4548 2785 2471 2392
    Total Assets 112697 110979 112241 117453 118464
    Property/Plant/Equipment, Total - Net 10344 12277 12348 12195 11731
    Goodwill, Net 23416 29522 29481 29301 28668
    Intangibles, Net 26418 28003 30451 31644 31888
    Long Term Investments 2122 2433 2555 2554 2491
    Other Long Term Assets, Total 4737 5251 5292 4849 6732
    Total Current Liabilities 48393 31909 30549 28656 28160
    Accounts Payable 3870 5350 5426 5146 4693
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 5602 8496 7166 6127 7204
    Other Current Liabilities, Total 38921 18063 17957 17383 16263
    Total Liabilities 74533 59132 60182 58111 57644
    Total Long Term Debt 19521 19804 21985 21782 21235
    Long Term Debt 18068 18259 20396 20244 19732
    Capital Lease Obligations 1453 1545 1589 1538 1503
    Deferred Income Tax 2457 2526 2727 2686 2719
    Minority Interest 81 84 83 81 78
    Other Liabilities, Total 4081 4809 4838 4906 5452
    Total Equity 38164 51847 52059 59342 60820
    Common Stock 825 842 842 890 890
    Retained Earnings (Accumulated Deficit) 37371 51057 51253 58544 60000
    Treasury Stock - Common -32 -52 -36 -92 -70
    Total Liabilities & Shareholders’ Equity 112697 110979 112241 117453 118464
    Total Common Shares Outstanding 2055.46 2068.26 2097.4 2119.61 2150.98
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 6955 24018 8071 7147 12800
    Cash From Operating Activities 14236 15071 13650 13625 14272
    Cash From Operating Activities 1873 1807 2088 1852 1783
    Amortization 5308 4306 4376 3974 3428
    Non-Cash Items 4404 -11714 3842 3369 -2315
    Cash Taxes Paid 1975 2342 1833 1876 1506
    Cash Interest Paid 696 664 703 793 816
    Changes in Working Capital -4304 -3346 -4727 -2717 -1424
    Cash From Investing Activities 1468 4208 -13182 -2226 -5591
    Capital Expenditures -2671 -2971 -2585 -2257 -2648
    Other Investing Cash Flow Items, Total 4139 7179 -10597 31 -2943
    Cash From Financing Activities -20562 -16264 -2208 -13627 -4244
    Financing Cash Flow Items 55 94 -199 3307 -119
    Total Cash Dividends Paid -7506 -7368 -6987 -6645 -6966
    Issuance (Retirement) of Stock, Net -10552 -3004 -2094 -5332 -1336
    Issuance (Retirement) of Debt, Net -2559 -5986 7072 -4957 4177
    Foreign Exchange Effects -32 -266 286 69 -26
    Net Change in Cash -4890 2749 -1454 -2159 4411
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line 2294 6955 5489 3914 2219
    Cash From Operating Activities 2957 14236 10125 5404 1649
    Cash From Operating Activities 377 7181 5233 3207 1405
    Amortization 1619
    Non-Cash Items 1085 4404 3417 2164 918
    Cash Taxes Paid 348 1975 1559 1239 633
    Cash Interest Paid 123 696 475 308 110
    Changes in Working Capital -2418 -4304 -4014 -3881 -2893
    Cash From Investing Activities 10621 1468 2935 -2263 9365
    Capital Expenditures -470 -2671 -2024 -1442 -859
    Other Investing Cash Flow Items, Total 11091 4139 4959 -821 10224
    Cash From Financing Activities -9202 -20562 -16568 -11830 -9528
    Financing Cash Flow Items -169 55 99 97 22
    Total Cash Dividends Paid -7255 -7506 -7506 -7506 -7506
    Issuance (Retirement) of Stock, Net -2727 -10552 -7874 -5156 -2448
    Issuance (Retirement) of Debt, Net 949 -2559 -1287 735 404
    Foreign Exchange Effects 107 -32 -173 -93 -41
    Net Change in Cash 4483 -4890 -3681 -8782 1445

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Novartis ADR Company profile

    Novartis (NVS) provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. The company has been honoured and received numerous awards for progress in research and development, their working environment, and their corporate responsibility activities. Novartis shares are listed and traded on the SIX Swiss Exchange (symbol “NOVN”) as well as on the New York Stock Exchange in the form of ADR (symbol “NVS”). Get all the latest on Novartis Repsg (NVS) share price at Capital.com.
    Industry: Pharmaceuticals (NEC)

    Lichtstrasse 35
    BASEL
    BASEL-STADT 4056
    CH

    Income Statement

    • Annual
    • Quarterly

    News

    We’re partnering with Newsquawk

    Filter out the noise and focus on the news that matters.

    08:32, 23 April 2024

    US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft

    The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.

    15:56, 22 April 2024

    Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

    Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

    07:56, 17 April 2024

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    People also watch

    XRP/USD

    0.55 Price
    -3.020% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    ETH/USD

    3,243.07 Price
    +1.660% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    BTC/USD

    66,817.35 Price
    +0.450% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    US100

    17,591.00 Price
    +2.230% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading